title: The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.
abstract: Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the first oxidase in the process of prostaglandin production from arachidonic acid. COX enzyme may be involved in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-gamma is a ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-gamma plays a role in both adipocyte differentiation and carcinogenesis. PPAR-gamma is one target for cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and PPAR-gamma in human prostate cancer tissues as well as the effects of COX-2 and LOX inhibitors and PPAR-gamma ligand.
authors.affiliation: Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors.forename: Masahide
authors.initials: M
authors.lastname: Matsuyama
authors.forename: Rikio
authors.initials: R
authors.lastname: Yoshimura
references.citation: Clin Cancer Res. 2005 Mar 1;11(5):1999-2007
references.pmid: 15756026
references.citation: Biochem Biophys Res Commun. 2004 Mar 12;315(3):624-35
references.pmid: 14975747
references.citation: Cancer. 2000 Aug 1;89(3):589-96
references.pmid: 10931458
references.citation: Cell Growth Differ. 2000 Jan;11(1):49-61
references.pmid: 10672903
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1710-6
references.pmid: 15533897
references.citation: Neoplasia. 2004 Nov-Dec;6(6):821-30
references.pmid: 15720809
references.citation: J Clin Invest. 2000 Jul;106(2):189-97
references.pmid: 10903334
references.citation: Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14
references.pmid: 17447067
references.citation: Cancer Lett. 2003 Feb 28;191(1):67-74
references.pmid: 12609711
references.citation: Am J Physiol. 1991 Feb;260(2 Pt 1):L13-28
references.pmid: 1899973
references.citation: Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2692-6
references.pmid: 1849272
references.citation: Prostate. 2000 Jan;42(1):73-8
references.pmid: 10579801
references.citation: Biochem Biophys Res Commun. 2003 Jul 25;307(2):342-9
references.pmid: 12859962
references.citation: Cancer Sci. 2007 Sep;98(9):1417-23
references.pmid: 17645780
references.citation: Nature. 1996 Nov 7;384(6604):39-43
references.pmid: 8900274
references.citation: J Med Chem. 2004 Dec 2;47(25):6195-206
references.pmid: 15566290
references.citation: PPAR Res. 2008;2008:249849
references.pmid: 18317513
references.citation: Biochem Biophys Res Commun. 2001 Sep 28;287(3):727-32
references.pmid: 11563856
references.citation: Anticancer Res. 2007 Jul-Aug;27(4B):2393-402
references.pmid: 17695530
references.citation: J Urol. 1998 Oct;160(4):1220-9
references.pmid: 9751323
references.citation: Cancer Res. 1995 Sep 1;55(17):3785-9
references.pmid: 7641194
references.citation: Prostate. 2002 May 1;51(2):108-16
references.pmid: 11948965
references.citation: Int J Mol Med. 2004 Jun;13(6):789-93
references.pmid: 15138613
references.citation: J Urol. 2003 Nov;170(5):1994-9
references.pmid: 14532840
references.citation: Oncol Rep. 2007 Jul;18(1):99-104
references.pmid: 17549353
references.citation: Biochim Biophys Acta. 1996 Nov 11;1304(1):65-84
references.pmid: 8944751
references.citation: Endocrinology. 1996 Jan;137(1):354-66
references.pmid: 8536636
references.citation: Biochem Biophys Res Commun. 2000 Apr 13;270(2):400-5
references.pmid: 10753637
references.citation: Int J Mol Med. 2004 May;13(5):665-8
references.pmid: 15067367
references.citation: BMC Cancer. 2006 Mar 06;6:53
references.pmid: 16519808
references.citation: Urology. 2000 Oct 1;56(4):671-6
references.pmid: 11018637
references.citation: J Urol. 2000 Sep;164(3 Pt 1):820-5
references.pmid: 10953162
references.citation: J Biol Chem. 1997 Mar 21;272(12):8071-6
references.pmid: 9065481
references.citation: Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13182-7
references.pmid: 9789062
references.citation: Nature. 1990 Oct 18;347(6294):645-50
references.pmid: 2129546
references.citation: J Biol Chem. 2000 Apr 14;275(15):11397-403
references.pmid: 10753955
references.citation: Clin Cancer Res. 2003 Aug 15;9(9):3503-13
references.pmid: 12960143
references.citation: Prostate. 2006 Feb 15;66(3):257-65
references.pmid: 16175586
references.citation: Int J Oncol. 2004 Apr;24(4):821-7
references.pmid: 15010818